Cargando…

Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation

Cyclosporine A-nanosuspensions were prepared using zirconium oxide beads as a milling media, Poloxamer 407 as a stabilizer and distilled water as an aqueous medium using the Pearl Milling technique. The optimized formulation was characterized in terms of particle size distribution, surface morpholog...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakarani, Mahendra, Patel, Priyal, Patel, Jayvadan, Patel, Pankaj, Murthy, Rayasa S. R., Vaghani, Subhash S.
Formato: Texto
Lenguaje:English
Publicado: Österreichische Apotheker-Verlagsgesellschaft 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002797/
https://www.ncbi.nlm.nih.gov/pubmed/21179351
http://dx.doi.org/10.3797/scipharm.0908-12
_version_ 1782193785433751552
author Nakarani, Mahendra
Patel, Priyal
Patel, Jayvadan
Patel, Pankaj
Murthy, Rayasa S. R.
Vaghani, Subhash S.
author_facet Nakarani, Mahendra
Patel, Priyal
Patel, Jayvadan
Patel, Pankaj
Murthy, Rayasa S. R.
Vaghani, Subhash S.
author_sort Nakarani, Mahendra
collection PubMed
description Cyclosporine A-nanosuspensions were prepared using zirconium oxide beads as a milling media, Poloxamer 407 as a stabilizer and distilled water as an aqueous medium using the Pearl Milling technique. The optimized formulation was characterized in terms of particle size distribution, surface morphology, drug-surfactant interaction, drug content, saturation solubility, osmolarity, and stability. The nanoparticles consisting of Poloxamer-bound cyclosporin A with a mean diameter of 213 nm revealed a spherical shape and 5.69 fold increased saturation solubility as compared to the parent drug. The formulation was found to be iso-osmolar with blood and stable up to 3 months at 2–8°C. In-vivo studies were carried out in albino rats and the pharmacokinetic parameters were compared with a marketed formulation, which indicated better results of the prepared formulation than the marketed one.
format Text
id pubmed-3002797
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Österreichische Apotheker-Verlagsgesellschaft
record_format MEDLINE/PubMed
spelling pubmed-30027972010-12-22 Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation Nakarani, Mahendra Patel, Priyal Patel, Jayvadan Patel, Pankaj Murthy, Rayasa S. R. Vaghani, Subhash S. Sci Pharm Original Papers Cyclosporine A-nanosuspensions were prepared using zirconium oxide beads as a milling media, Poloxamer 407 as a stabilizer and distilled water as an aqueous medium using the Pearl Milling technique. The optimized formulation was characterized in terms of particle size distribution, surface morphology, drug-surfactant interaction, drug content, saturation solubility, osmolarity, and stability. The nanoparticles consisting of Poloxamer-bound cyclosporin A with a mean diameter of 213 nm revealed a spherical shape and 5.69 fold increased saturation solubility as compared to the parent drug. The formulation was found to be iso-osmolar with blood and stable up to 3 months at 2–8°C. In-vivo studies were carried out in albino rats and the pharmacokinetic parameters were compared with a marketed formulation, which indicated better results of the prepared formulation than the marketed one. Österreichische Apotheker-Verlagsgesellschaft 2010 2010-04-26 /pmc/articles/PMC3002797/ /pubmed/21179351 http://dx.doi.org/10.3797/scipharm.0908-12 Text en © Nakarani et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Papers
Nakarani, Mahendra
Patel, Priyal
Patel, Jayvadan
Patel, Pankaj
Murthy, Rayasa S. R.
Vaghani, Subhash S.
Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation
title Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation
title_full Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation
title_fullStr Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation
title_full_unstemmed Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation
title_short Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation
title_sort cyclosporine a-nanosuspension: formulation, characterization and in vivo comparison with a marketed formulation
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002797/
https://www.ncbi.nlm.nih.gov/pubmed/21179351
http://dx.doi.org/10.3797/scipharm.0908-12
work_keys_str_mv AT nakaranimahendra cyclosporineananosuspensionformulationcharacterizationandinvivocomparisonwithamarketedformulation
AT patelpriyal cyclosporineananosuspensionformulationcharacterizationandinvivocomparisonwithamarketedformulation
AT pateljayvadan cyclosporineananosuspensionformulationcharacterizationandinvivocomparisonwithamarketedformulation
AT patelpankaj cyclosporineananosuspensionformulationcharacterizationandinvivocomparisonwithamarketedformulation
AT murthyrayasasr cyclosporineananosuspensionformulationcharacterizationandinvivocomparisonwithamarketedformulation
AT vaghanisubhashs cyclosporineananosuspensionformulationcharacterizationandinvivocomparisonwithamarketedformulation